RNA_Biotech

Stocks - Biotech - RNAi, mRNA, RNA tech, gene therapy, CRISPR - opinions, news, trading. Top Pick for 2026 $MDNAF $MDNA (.to)

[RNA_Biotech @RNA_Biotech]

Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

$MDNA (.to) $MDNAF

https://t.co/SEWZ4wso8Y

[RNA_Biotech @RNA_Biotech]

$MDNA $MDNAF

[Joe @Gantosj]

Interesting to see $MDNAF $MDNA.to secure the largest portion of the financing; a solid $8M coming from the U.K. investment fund "Sorbie Bornholm".

According to the prospectus, the company plans to issue a minimum of 6M Units and up to 10M Units at $0.50 per Unit, for total gross proceeds between $3M and $5M
A strong structure that reinforces confidence in the financing strategy and the MDNA11 development path.
https://t.co/fwBvN6i4TX

[RNA_Biotech @RNA_Biotech]

$MDNA $MDNAF Public Offering of Securities

$0.50 and one half of one warrant $0.65

https://t.co/rugjfg9HuA

[RNA_Biotech @RNA_Biotech]

$MDNAF $MDNA

[Medicenna Therapeutics @Medicenna1]

Why is MDNA11 being evaluated at the “neoajuvant” setting for Melanoma? It’s about timing. Dosing the first patient in our NEO-CYT trial at up to 12 centers in Italy marks a strategic shift toward potentially curative care.

🧵 (1/4) $MDNA.TO $MDNAF

[RNA_Biotech @RNA_Biotech]

Very important progress with MDNA11

$MDNAF $MDNA.TO

[Medicenna Therapeutics @Medicenna1]

$MDNAF $MDNA.TO Big news from Medicenna: The first patient has been dosed in the Phase 1b NEO-CYT study! This randomized, multi-centre trial evaluates MDNA11 + nivolumab (± ipilimumab) at up to 12 centers in Italy.

[RNA_Biotech @RNA_Biotech]

Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026

$MDNAF $MDNA

https://t.co/SxL7FOIIPb

[RNA_Biotech @RNA_Biotech]

@semodough yep, difficult for investors. You want to see them have cash, only problem, we can not see the reason nothing is happening. No interestest? Terms not good enough for CEO? possible deal for MDNA11 or MDNA55 soon? buyout? $MDNA $MDNAF

[RNA_Biotech @RNA_Biotech]

Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

MDNA113 vs anti-PD-1 x IL-2α demonstrates superior tolerability, significantly wider therapeutic window

$MDNAF $MDNA

https://t.co/cIkKuVTYC0

[GypsyNoLonger @GypsyNoLonger]

$MDNAF $MDNA.TO $XBI They have the Map. They have the Machine. They have the Workarounds. What they don’t have is the one layer that decides whether any of it actually works.

Tomorrow: first real look at MDNA113 — the conditionally activated bispecific designed to execute without recreating the failure mode.
https://t.co/jqMq146L8y

[RNA_Biotech @RNA_Biotech]

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

$MDNA $MDNAF

https://t.co/k2kksDpDxz

[Medicenna Therapeutics @Medicenna1]

We are pleased to welcome Dr. Nageatte Ibrahim as Chief Medical Officer (fractional) at Medicenna. With >20 years of oncology experience, her leadership will be pivotal as we advance our immunotherapy pipeline.
$MDNAF $MDNA.TO

[Medicenna Therapeutics @Medicenna1]

As we prep to share our latest #MDNA113 data at #AACR26, the #ImmunoOncology space is officially heating up!
There is a MASSIVE push in pharma for PD-1 bispecifics. We're seeing >$43 BILLION in recent combined transaction value in this space alone. $MDNAF $MDNA.TO

[RNA_Biotech @RNA_Biotech]

$mdna $mdnaf

[Medicenna Therapeutics @Medicenna1]

Unlocking immunologically "cold" tumors is one of oncology's greatest challenges.
We are thrilled to announce that Medicenna will present highly anticipated preclinical data for our first-in-class IL-2-PD-1 Superkine, #MDNA113, at #AACR26 in San Diego!
Read the full PR here: https://t.co/jxN5BlBtBr

$MDNAF $MDNA.TO #Biotech #Oncology #Immunotherapy #CancerResearch

(Disclaimer: MDNA113 is investigational. Post contains forward-looking statements. See SEDAR/SEC filings for risks).

[Joe @Gantosj]

$MDNAF $MDNA.to to present MDNA-113 at #AACR26 04/21/2026

Notably, immunodynamic and safety data from non-human primate studies will highlight the differentiated profile of MDNA113
https://t.co/RSiYZ90p4W

[RNA_Biotech @RNA_Biotech]

$MDNAF is showing serious strength. 📈

• Up 27% from recent lows
• Reclaimed the 20-Day MA✅
• Cleared the 50-Day MA ✅
• Eyes on the 200-Day MA next 🎯

$MDNA $XBI #Biotech #StockMarket

[RNA_Biotech @RNA_Biotech]

$MDNA $MDNAF

7th Annual Glioblastoma Summit: February 19

BIO Investment and Growth Summit : March 2-3

38th Annual ROTH Conference: March 22-24

BIO-Europe Spring Conference: March 23-25

[Medicenna Therapeutics @Medicenna1]

$MDNAF $MDNA.TO Medicenna is hitting the road! Today we announced our Spring 2026 conference lineup.

Kicking off TOMORROW in Boston: CEO Dr. Fahar Merchant presents clinical updates on bizaxofusp in recurrent #Glioblastoma at the 7th Annual GBM Summit.

🔗 PR:https://t.co/7DSBKbum11

🧵 1/2

[RNA_Biotech @RNA_Biotech]

Medicenna Third Quarter Fiscal 2026

ABILITY-1 new expansion cohort NSCLC and colorectal cancer (mono- and combination in TMB-H and MSI-H cohorts) (both have blockbuster market opportunities)

$MDNA $MDNAF

https://t.co/0NF1wW6mj4

[RNA_Biotech @RNA_Biotech]

$MDNAF $MDNA

great work by David: PRISM-11 external scientific-intelligence and interpretive framework now used by the company

https://t.co/2gcD8EtaCU

[RNA_Biotech @RNA_Biotech]

$MDNA $MDNAF

[RNA_Biotech @RNA_Biotech]

Participants: 80 participants
Sites: 8 sites in 1 country

This is probably a $15M+ trial that Fondazione Melanoma Onlus will be funding.

$MDNAF $MDNA

[RNA_Biotech @RNA_Biotech]

A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11....

$MDNA $MDNAF

https://t.co/bYp7hNCO15

[RNA_Biotech @RNA_Biotech]

Overall trial status:

" Authorised, recruitment pending"

Lots of work has already been done. Trial is further along than most would think.

$MDNAF $MDNA